ArticleNeuro-oncology2026

VITA-GBM: EPIC-0502-driven HIF1α degradation overcomes bevacizumab resistance and synergizes with TMZ in glioblastoma.

Yaqing Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.